ProjectRoche Pasadena BP39529
Basic data
Title:
Roche Pasadena BP39529
Duration:
01/04/2018 to 31/07/2020
Abstract / short description:
A randomized, double-blind, placebo-controlled, 52-Week Phase II Study to evaluate the efficacy of intravenous RO7046015 (PRX002) in Participants with early Parkinson's Disease with a 52-Week blinded Extension Pasadena
Involved staff
Managers
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Contact persons
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Department of Psychology
Faculty of Science
Faculty of Science
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
Department of Neurology with Focus on Neurodegenerative Disorders
University Department of Neurology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Basel, Switzerland